Search research articles
Contact Us
Filters
Showing results (201-210 of 211) with videos related to
Page
of 22
Sort By:
Advances in Experimental Medicine and Biology
|
September 29, 1999
Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)
R Advani, G Visani, D Milligan, et al.
Clinical Drug Investigation
|
March 29, 2008
Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off
M B Regazzi, D Russo, I Iacona, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 1998
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group
B Löwenberg, S Suciu, E Archimbaud, et al.
Leukemia
|
January 21, 2014
Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients
G Visani, F Ferrara, F Di Raimondo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2011
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients
L Pagano, C G Valentini, V De Stefano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2001
Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group
L Pagano, A Pulsoni, L Mele, et al.
Leukemia
|
January 30, 2004
Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials
L Pagano, A Pulsoni, M E Tosti, et al.
British Journal of Haematology
|
February 28, 2001
Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia
L Pagana, A Pulsoni, M E Tosti, et al.
The Pharmacogenomics Journal
|
December 6, 2017
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine
G Visani, F Loscocco, A Ruzzo, et al.
Blood
|
August 1, 1997
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups
F Mandelli, D Diverio, G Avvisati, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 211) with videos related to
Sort By:
Page
of 22
Advances in Experimental Medicine and Biology
|
September 29, 1999
Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)
R Advani, G Visani, D Milligan, et al.
Clinical Drug Investigation
|
March 29, 2008
Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off
M B Regazzi, D Russo, I Iacona, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 1998
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group
B Löwenberg, S Suciu, E Archimbaud, et al.
Leukemia
|
January 21, 2014
Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients
G Visani, F Ferrara, F Di Raimondo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2011
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients
L Pagano, C G Valentini, V De Stefano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2001
Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group
L Pagano, A Pulsoni, L Mele, et al.
Leukemia
|
January 30, 2004
Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials
L Pagano, A Pulsoni, M E Tosti, et al.
British Journal of Haematology
|
February 28, 2001
Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia
L Pagana, A Pulsoni, M E Tosti, et al.
The Pharmacogenomics Journal
|
December 6, 2017
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine
G Visani, F Loscocco, A Ruzzo, et al.
Blood
|
August 1, 1997
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups
F Mandelli, D Diverio, G Avvisati, et al.
Page
of 22